Lee Seung Jae, Hwang Dae Wook, Lee Jae Hoon, Song Ki Byung, Lee Woohyung, Park Yejong, Kim Song Cheol
Department of Surgery, Konyang University Hospital, Konyang University College of Medicine, Daejeon, Korea.
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Gland Surg. 2022 Oct;11(10):1590-1603. doi: 10.21037/gs-22-304.
The aim of this study is to identify prognostic factors and the best candidates for neoadjuvant therapy among patients with resectable left-sided pancreatic ductal adenocarcinoma (PDAC) by analyzing the timing and pattern of recurrence following upfront surgery.
This single-center retrospective study included patients with resectable left-sided PDAC who underwent upfront distal pancreatectomy from 2005 to 2015. A minimum P value approach was used to evaluate the optimal cutoff of early recurrence. The predictors of recurrence were assessed with Cox regression analysis.
Among 311 included patients, 241 (77.5%) had a recurrence at a median follow-up of 29.3 months. Systemic recurrence occurred in 194 patients (80.5%) and isolated local recurrence in 47 patients (19.5%). A recurrence-free survival cutoff of 12 months was selected to distinguish between early and late recurrence. The patients with early recurrence had a shorter median overall survival (16.1 39.9 months, P<0.001) and post-recurrence survival (9.6 17.2 months, P<0.001) than those with late recurrence. The patients with systemic recurrence had a shorter median overall survival (19.6 29.1 months, P=0.007) and post-recurrence survival (11.0 15.3 months, P=0.024) than those with an isolated local recurrence. In multivariable analysis, preoperative CA 19-9 ≥500 U/mL [odd ratio (OR) 2.037, P=0.035], radiologic splenic vessels invasion (OR 5.014, P<0.001), positive radial resection margin (OR 2.638, P<0.001), and no adjuvant chemotherapy (OR 2.084, P=0.001) were predictors of an early systemic recurrence.
Radiologic splenic vessels invasion may be considered to indicate a biologically borderline status in patients with anatomically resectable left-sided PDAC. Future clinical trials of neoadjuvant therapy targeting these patients should be conducted.
本研究旨在通过分析初次手术后复发的时间和模式,确定可切除的左侧胰腺导管腺癌(PDAC)患者的预后因素以及新辅助治疗的最佳候选者。
这项单中心回顾性研究纳入了2005年至2015年期间接受初次远端胰腺切除术的可切除左侧PDAC患者。采用最小P值法评估早期复发的最佳临界值。通过Cox回归分析评估复发的预测因素。
在纳入的311例患者中,241例(77.5%)在中位随访29.3个月时出现复发。194例患者(80.5%)发生全身复发,47例患者(19.5%)发生孤立性局部复发。选择12个月的无复发生存期临界值来区分早期和晚期复发。早期复发患者的中位总生存期(16.1对39.9个月,P<0.001)和复发后生存期(9.6对17.2个月,P<0.001)均短于晚期复发患者。全身复发患者的中位总生存期(19.6对29.1个月,P=0.007)和复发后生存期(11.0对15.3个月,P=0.024)均短于孤立性局部复发患者。在多变量分析中,术前CA 19-9≥500 U/mL[比值比(OR)2.037,P=0.035]、影像学脾血管侵犯(OR 5.014,P<0.001)、阳性切缘(OR 2.638,P<0.001)和未接受辅助化疗(OR 2.084,P=0.001)是早期全身复发的预测因素。
影像学脾血管侵犯可被视为解剖学上可切除的左侧PDAC患者生物学临界状态的指标。应针对这些患者开展新辅助治疗的未来临床试验。